Literature DB >> 8394749

Association of rhinovirus infection with poor bacteriologic outcome of bacterial-viral otitis media.

B S Sung1, T Chonmaitree, L D Broemeling, M J Owen, J A Patel, D C Hedgpeth, V M Howie.   

Abstract

Viruses--both alone and in combination with bacteria--have been shown to be a cause of acute otitis media (AOM). Moreover, the presence of virus in middle ear fluid (MEF) interferes with the bacteriologic response to antibiotic treatment in AOM. We studied various factors related to the eradication of bacteria from the MEF of infants and children who had AOM associated with a combination of bacteria and viruses. Of 622 cases of AOM diagnosed and treated between 1985 and 1991, 71 were due to such a combination. Bacteria were eradicated from MEF by 2-4 days of antibiotic treatment in 50 (70%) of these 71 cases; in the remaining 21 cases, the originally identified bacteria persisted or a new pathogenic bacterial species was detected after such treatment. These two groups of cases were compared with respect to the patients' age, sex, race, history of recurrent AOM, duration of respiratory symptoms, and compliance; the type of antibiotic treatment administered; the type of pathogenic bacteria and viruses identified in MEF; the presence of single or multiple pathogens; and the laterality of the disease. The only difference noted was in the type(s) of virus found in MEF. The presence of rhinovirus was associated with a higher rate of bacteriologic failure than was that of respiratory syncytial virus, parainfluenza virus, influenza virus, or other viruses. Our data suggest that the bacteriologic response to antibiotic treatment in bacterial-viral AOM may depend in part on the type(s) of virus present in MEF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394749     DOI: 10.1093/clinids/17.1.38

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR.

Authors:  A Pitkäranta; E Arruda; H Malmberg; F G Hayden
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

Review 2.  Antibiotic theory in otitis media.

Authors:  A Gungor; C D Bluestone
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

3.  Blinded multiplex PCR analyses of middle ear and nasopharyngeal fluids from chinchilla models of single- and mixed-pathogen-induced otitis media.

Authors:  L O Bakaletz; G J White; J C Post; G D Ehrlich
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

4.  Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis.

Authors:  S M Kuhn; J Preiksaitis; G J Tyrrel; T Jadavji; D Church; H D Davies
Journal:  Can J Infect Dis       Date:  2001-01

Review 5.  Importance of respiratory viruses in acute otitis media.

Authors:  Terho Heikkinen; Tasnee Chonmaitree
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 6.  Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention.

Authors:  F G Hayden
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

Review 7.  Viral upper respiratory tract infections in young children with emphasis on acute otitis media.

Authors:  Johanna Nokso-Koivisto; Tapani Hovi; Anne Pitkäranta
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2006-03-27       Impact factor: 1.675

Review 8.  Immunopathogenesis of polymicrobial otitis media.

Authors:  Lauren O Bakaletz
Journal:  J Leukoc Biol       Date:  2009-10-20       Impact factor: 4.962

Review 9.  Viral-bacterial interactions in acute otitis media.

Authors:  Tal Marom; Johanna Nokso-Koivisto; Tasnee Chonmaitree
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

Review 10.  Human rhinoviruses: the cold wars resume.

Authors:  Ian M Mackay
Journal:  J Clin Virol       Date:  2008-05-27       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.